share_log

Piper Sandler Reiterates Overweight on Moderna, Lowers Price Target to $69

Benzinga ·  Nov 18 17:20  · Ratings

Piper Sandler analyst Edward Tenthoff reiterates Moderna (NASDAQ:MRNA) with a Overweight and lowers the price target from $115 to $69.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment